Merck Announces Pause In Enrollment For Two Phase 3 Clinical Trials Of Investigational, Once-Monthly, Oral Islatravir For Pre-Exposure Prophylaxis (Prep) Of HIV-1 Infection

Reuters2021-12-07

Merck & Co Inc:Merck Announces Pause In Enrollment For Two Phase 3 Clinical Trials Of Investigational, Once-Monthly, Oral Islatravir For Pre-Exposure Prophylaxis (Prep) Of Hiv-1 Infection.

Merck & Co Inc - Enrolled Participants Will Continue To Receive Study Medicine.Merck & Co Inc - Informed By Recommendations Of Prep Edmc, Merck Is Implementing Additional Monitoring Measures For Study Participants.

Merck & Co Inc - Additional Monitoring Measures For Study Participants Include Increasing Frequency Of Total Lymphocyte And Cd4+ T-Cell Assessments.

Merck - At Isl Prep Edmc Recommendation, Pausing Impower 22, Impower 24 Enrollment While Co Conducts Further Analyses Of These, Other Ongoing Studies.Merck & Co Inc - Investigators Have Been Informed Of Actions Co Is Taking.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

  • 飙高音
    2021-12-07
    飙高音
    Great ariticle, would you like to share it?
  • LWayne
    2021-12-07
    LWayne
    Ha
  • SeanSak
    2021-12-07
    SeanSak
    Like n comment
发表看法
3